The UK government has accepted all 44 recommendations from an independent commission on the regulation of artificial intelligence in healthcare, marking a major step towards tighter oversight of AI-powered medical technologies.
The government announced the decision on 6 October 2026, promising a new regulatory approach that will monitor AI-enabled medical devices throughout their working life rather than relying mainly on assessments conducted before they enter the market.
The move is designed to allow the NHS and patients to benefit from rapidly developing AI technologies while strengthening safeguards around patient safety, transparency, accountability and public trust.
From one-time approval to continuous monitoring
One of the biggest changes proposed by the government is a shift from a largely one-off assessment of AI medical devices towards lifecycle-based regulation.
Under the new approach, AI systems will be monitored after deployment to assess how they perform in real-world healthcare settings. This is particularly important because AI systems can change and improve over time, meaning their performance after deployment may differ from their initial assessment.
The government says the Medicines and Healthcare products Regulatory Agency (MHRA) will develop stronger post-market surveillance, allowing regulators to identify changes in quality, safety and performance as AI technologies are used in practice.
The National Commission first published its recommendations on 10 September 2026. Its central conclusion was that AI healthcare regulation should become more proportionate, lifecycle-based and system-wide.
44 recommendations accepted in full
The recommendations cover a wide range of issues, including how AI medical devices are classified, how they are monitored, how responsibilities are divided between organisations and how patients are informed when AI is involved in their care.
The government has accepted all 44 recommendations and identified several priority areas for implementation.
These include modernising the regulatory framework for AI-enabled medical devices, improving access and outcomes for underserved groups, strengthening post-market monitoring and clarifying who is responsible when AI technologies are used in healthcare.
The government also plans to improve AI literacy among healthcare professionals, procurement teams and other staff involved in the adoption of AI.
A full implementation roadmap covering all 44 recommendations is expected by spring 2027.
Health Minister: innovation cannot come before safety
Health Innovation Minister James Frith said the government wants patients to benefit from AI while ensuring that new technologies are properly overseen.
“Innovation must never come at the expense of patient safety.”
Frith said accepting all 44 recommendations would provide a foundation for using AI in healthcare while keeping safeguards, transparency and public confidence at the centre of its use.
The government says AI could help doctors deliver better care, improve outcomes and give healthcare professionals more time to focus on patients.
But the policy recognises that simply approving an AI system is not enough. Its performance must continue to be evaluated once it is being used with real patients.
MHRA opens new AI testing programme
Alongside the government’s announcement, the MHRA has opened applications for the third phase of its AI Airlock programme.
AI Airlock is a regulatory sandbox designed to allow developers, regulators and healthcare partners to test AI-enabled medical devices in a controlled environment.
The third phase will focus specifically on post-market surveillance and lifecycle regulation, reflecting the new approach announced by the government.
Applications are open now, with a webinar for prospective applicants scheduled for 22 October 2026. The first group of innovators is expected to be selected in November 2026.
The MHRA says the programme has also secured three additional years of government funding following its earlier pilot and second phase.
Patients to have a greater say
The reforms are not only about regulating technology. They also aim to give patients more information and involvement in decisions about AI.
The government’s response includes a commitment to consider clearer transparency requirements around when AI is used in patient care and what choices patients should have.
The MHRA will also work with partners on patient and public engagement and consider ways of providing clearer public information about the safety of AI-enabled medical devices.
One proposed measure is a regularly updated public list of authorised AI-enabled medical devices in the UK.
Professor Henrietta Hughes OBE, Deputy Chair of the National Commission and Patient Safety Commissioner for England, said patients had made their priorities clear.
“Patients have told us they want artificial intelligence that improves care without compromising safety, transparency or accountability.”
She welcomed the commitment to monitoring AI throughout its use and strengthening patient involvement in decision-making.
More training for healthcare professionals
Another major element of the reforms is AI literacy.
The government plans to support a coordinated approach to training healthcare professionals, procurement teams, regulators and other staff so they have a basic understanding of AI and can use these technologies responsibly.
The aim is not to turn doctors and nurses into AI specialists, but to ensure that professionals understand the capabilities and limitations of the systems they may use.
The government response says training should be adapted to people’s different roles and responsibilities across the healthcare system.
AI regulation enters a new phase
Lawrence Tallon, Chief Executive of the MHRA, described the commission’s recommendations as a blueprint for making the UK a place where AI products can reach patients safely and quickly.
He said the AI Airlock programme would help regulators understand how technologies can be implemented and monitored throughout their working life.
The government’s decision represents a significant change in how Britain plans to govern AI in healthcare.
Rather than treating approval as the end of the regulatory process, the new approach treats it as the beginning of an ongoing relationship between AI developers, regulators, healthcare professionals and patients.
For London, home to major NHS institutions, universities, technology companies and a growing health-tech ecosystem, the changes could have particular significance as AI becomes increasingly integrated into medical research, diagnosis, administration and patient care.
The challenge now will be turning the government’s 44 accepted recommendations into practical safeguards without slowing down technologies that could genuinely improve healthcare.
The next major milestone will come in spring 2027, when the government plans to publish its full implementation roadmap.
Until then, Britain’s message is clear: AI can play a larger role in healthcare, but its benefits must be matched by continuous oversight, transparency and patient safety.
